• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Humane Society urges European Union to lead cutting-edge research

Humane Society urges European Union to lead cutting-edge research

January 24, 2012
CenterWatch Staff

Humane Society International/Europe (HSI) urged the European Union to lead the world in cutting-edge research and testing as it kicked off discussions about how to spend its Horizon 2020 research funding budget. Horizon 2020, devised to strengthen the E.U.’s position in science, is being debated by the E.U. Parliament’s Industry, Research and Energy Committee.

Horizon 2020 combines funding from E.U. Framework programs, the European Research Council and elsewhere, and aims to support science excellence and innovation. HSI Europe said by funding advanced research at the cutting edge of science, Horizon 2020 will better equip E.U. scientists to tackle the major human and environmental health challenges of the 21st century.

Troy Seidle, director of research and toxicology for Humane Society International/Europe, said, “If Horizon 2020’s key objective of supporting science excellence is to be achieved, it is vital that substantial funding is focused on advanced, human-relevant research and testing methods. By investing in the development of emerging and future research technologies, we can harness the very latest human health and drug discovery advances that science has to offer and improve the quality of our medical research endeavors. Supporting industries today that are inventing the science techniques of tomorrow will also stimulate economic growth. In vitro and computational techniques represent science’s future and Horizon 2020 is Europe’s chance to make sure it is leading the way.”

According to HSI, advanced research such as state-of-the-art cellular, computer and robotic tools are already superseding many of the limitations of traditional methods, particularly the poor productivity of traditional animal-based approaches that can delay vital medical research. The FDA calculates that 92% of new drug candidates that appear safe and effective in animal studies fail when given to humans, said HSI. To reverse the slow pace of progress in key areas such as cancer, asthma and degenerative neurological disorders, far greater investment is needed in sophisticated tools and technologies more relevant to humans.

Improving the speed and relevance of chemical safety testing is also a priority concern of HSI in a number of E.U. policy areas, such as cosmetics and REACH chemicals legislation. A paradigm shift in safety testing is already underway with the slow and costly tests of the last century being replaced by high-speed, sophisticated techniques, it said.

 

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing